Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

138.70 +0.90 (+0.65%)
Streaming Delayed Price Updated: 10:41 AM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts
iRhythm raises 2025 sales forecast and launches Zio ECG system in Japan as analysts boost ratings and price targets on strong Q1 performance. 
Via Benzinga
Wells Fargo Upgrades iRhythm Technologies Stock, Raises Price Target To $130: Retail’s Thrilled
The firm’s new target on iRhythm implies a 19.7% upside to Thursday’s closing price. 
Via Stocktwits
This FTAI Aviation Analyst Turns Bullish; Here Are Top 2 Upgrades For Friday
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Breaking Down iRhythm Technologies: 6 Analysts Share Their Views
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday
Via Benzinga
Deep Dive Into iRhythm Technologies Stock: Analyst Perspectives (5 Ratings)
Via Benzinga
iRhythm (NASDAQ:IRTC) Surprises With Strong Q1, Full-Year Sales Guidance is Optimistic
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $158.7 million. The company’s... 
Via StockStory
iRhythm Launches Zio® Long-Term Continuous Monitoring Service in Japan as the Zio® ECG Recording and Analysis System, Advancing AI-Powered Arrhythmia Detection
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces First Quarter 2025 Financial Results
From iRhythm
Via GlobeNewswire
iRhythm Earnings: What To Look For From IRTC
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be reporting results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Exposures Artificial Intelligence Economy Tariff
iRhythm Technologies to Present at the Bank of America Securities 2025 Health Care Conference
From iRhythm
Via GlobeNewswire
iRhythm Presents New Real-World Data on Ambulatory Cardiac Monitoring at HRS 2025 Reinforcing Clinical Superiority of Zio Long-Term Continuous Monitoring
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Report First Quarter 2025 Financial Results on May 1, 2025
From iRhythm
Via GlobeNewswire
iRhythm Technologies Releases 2024 Corporate Sustainability Report That Demonstrates Ongoing Commitment to Culture of Quality and Sustainability
Report highlights progress against key sustainability initiatives that reflect iRhythm’s commitment to delivering better data, better insights, and better health for all 
From iRhythm
Via GlobeNewswire
3 Reasons IRTC is Risky and 1 Stock to Buy Instead
iRhythm has been on fire lately. In the past six months alone, the company’s stock price has rocketed 78.8%, reaching $102.62 per share. This was partly thanks to its solid quarterly results, and the... 
Via StockStory
Topics Bankruptcy
Exposures Financial Legal
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Small-Cap Stock Worth Your Attention and 2 to Question
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
iRhythm Unveils New Real-World Data at ACC.25 Demonstrating the Benefits of Zio® Long-Term Continuous Monitoring for Arrhythmia Detection
Two large studies of over one million patients reveal that short-term Holter-duration monitoring frequently misses actionable arrhythmias and that patient-reported symptoms are an unreliable predictor... 
From iRhythm
Via GlobeNewswire
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval. 
Via Investor's Business Daily
1 Growth Stock to Target This Week and 2 to Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
iRhythm (NASDAQ:IRTC) Reports Strong Q4, Stock Soars
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24% year on year to $164.3 million. The company expects... 
Via StockStory
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
From iRhythm
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.